Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application

Listing of Claims:

- 1. (Currently Amended) A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol, and an excipient comprising Poloxamer 188, and one or more additional excipients, wherein said composition is stored in a container having a means for dispensing the composition, and wherein the total propofol degradants of the solution when maintained at 25 °C, 40 °C, or 60 °C for 4 weeks are present in an amount of less than 5% (w/v) of said composition.
- 2. (Currently Amended) The composition of Claim 1, wherein said further comprising one or more additional excipients are-selected from the group consisting essentially of a purified poloxamer, Ammonium acetate, Benzalkonium chloride, Benzethonium chloride, Benzyl alcohol, Brij 35, Brij 97, Calcium gluceptate, ChlorobutanOL, Citric Acid, Cremophor EL, Deoxycholate, Diethanolamine, Ethanol, Gamma cyclodextrin, Glycerin, Lactobionic acid, Lysine, Magnesium chloride, Methylparaben, PEG 1000, PEG 300, PEG 3350, PEG 400, PEG 600, Poloxamer 237, Poloxamer 338, Poloxamer 407, Polyoxyethylene 100 stearate, Polyoxyethylene 40 stearate, Polyoxyethylene 50 stearate, Polysorbate 20, Polysorbate 80, Povidone, Propylene Glycol, Sodium acetate, Vitamine E TPGS, Sodium benzoate, and Sodium tartate.
- 3. (Currently Amended) The composition of Claim $\frac{12}{2}$, wherein said one or more additional excipients are a combination selected from the group consisting of:
 - a) Benzalkonium chloride, Cremophor EL;
 - b) Benzalkonium chloride, Poloxamer 237;
 - c) Benzalkonium chloride, Benzethonium chloride, Poloxamer 237;
 - d) Benzalkonium chloride, Cremophor EL, Polysorbate 80;
 - e) Benzalkonium chloride, Cremophor EL, Propylene Glycol;
 - gf) Benzalkonium chloride, PEG 400, Poloxamer 237;
 - hg) Benzalkonium chloride, Poloxamer 338;
 - jh) Benzalkonium chloride, Poloxamer 237, Polyoxyethylene 40 Stearate;

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

```
ki) Benzalkonium chloride, Poloxamer 237, Polysorbate 80;
lj) Benzalkonium chloride, Poloxamer 237, Propylene Glycol;
mk) Benzalkonium chloride, Poloxamer 237, vitamine E TPGS;
nl) Benzalkonium chloride, Poloxamer 237, Saccharin sodium;
em) Benzalkonium chloride, Poloxamer 338;
an) Benzalkonium chloride, Poloxamer 407;
FO) Benzalkonium chloride, Poloxamer 407, Polyoxyethylene 40 Stearate;
sp) Benzalkonium chloride, Poloxamer 407, Polysorbate 80;
tg) Benzalkonium chloride, Poloxamer 407, vitamine E TPGS;
ur) Benzethonium chloride, Cremophor EL;
vs) Benzethonium chloride, Cremophor EL, PEG 400;
wt) Benzethonium chloride, Cremophor EL, Poloxamer 237;
*u) Benzethonium chloride, Cremophor EL, Poloxamer 338;
yv) Benzethonium chloride, Cremophor EL, Poloxamer 407;
<u>zw</u>) Benzethonium chloride, Cremophor EL, Polysorbate 80;
aax) Benzethonium chloride, Cremophor EL, Propylene Glycol;
bby) Benzethonium chloride, Cremophor EL, vitamine E TPGS;
ddz) Benzethonium chloride, PEG 400;
[[ee]]aa) Benzethonium chloride, PEG 400, Poloxamer 237;
[[ff]]bb) Benzethonium chloride, PEG 400, Poloxamer 338;
[[qq]]cc) Benzethonium chloride, PEG 400, Poloxamer 407;
[[hh]]dd) Benzethonium chloride, PEG 400, Polyoxyethylene 40 Stearate;
[[ii]]ee) Benzethonium chloride, PEG 400, Polysorbate 80;
[[kk]]ff) Benzethonium chloride , Poloxamer 237;
[[II]]qq) Benzethonium chloride, Poloxamer 338;
[[mm]]hh) Benzethonium chloride, Poloxamer 407;
[[nn]]ii) Benzethonium chloride, Polyoxyethylene 40 Stearate;
[[oo]]jj) Benzethonium chloride, Polysorbate 80;
[[pp]]kk) Benzethonium chloride, Propylene Glycol;
[[qq]]II) Benzethonium chloride, vitamine E TPGS;
[[ss]]mm) Benzethonium chloride, Poloxamer 237;
[[tt]]nn) Benzethonium chloride, Poloxamer 237, Poloxamer 338;
```

[[uu]]oo) Benzethonium chloride, Poloxamer 237, Poloxamer 407;

Appln. No.: 10/629,308

Amendment Dated March 2, 2007

```
[[vv]]pp) Benzethonium chloride, Poloxamer 237, Polyoxyethylene 40 Stearate;
      [[ww]]qq) Benzethonium chloride, Poloxamer 237, Polysorbate 80;
      [[xx]]rr) Benzethonium chloride, Poloxamer 237, Propylene Glycol;
      [[yy]]ss) Benzethonium chloride, Poloxamer 237, vitamine E TPGS;
      [[bbb]]tt) Benzethonium chloride, Poloxamer 338, Poloxamer 407;
      [[ccc]]uu) Benzethonium chloride, Poloxamer 338, Polyoxyethylene 40 Stearate;
      [[ddd]]vv) Benzethonium chloride, Poloxamer 338, Polysorbate 80;
      [[ggg]]ww) Benzethonium chloride, Poloxamer 407;
      [[hhh]]xx) Benzethonium chloride, Poloxamer 407, Polyoxyethylene 40 Stearate;
      [[iii]]yy) Benzethonium chloride, Poloxamer 407, Polysorbate 80;
      [[jjj]]zz) Benzethonium chloride, Poloxamer 407, Propylene Glycol;
      [[kkk]]aaa) Benzethonium chloride, Poloxamer 407, vitamine E TPGS;
      [[mmm]]bbb) Benzethonium chloride, Polyoxyethylene 40 Stearate, Polysorbate
80;
      [[nnn]]ccc) Benzethonium chloride, Polyoxyethylene 40 Stearate, Propylene
Glycol;
      [[ooo]]ddd) Benzethonium chloride, Polyoxyethylene 40 Stearate, vitamine E
TPGS:
      [[ppp]]eee) Benzethonium chloride, Polyoxyethylene 40 Stearate;
      [[qqq]]fff) Benzethonium chloride, Polysorbate 80;
      [[rrr]]qqq) Benzethonium chloride, Polysorbate 80, Propylene Glycol;
      [[sss]]hhh) Benzethonium chloride, vitamine E TPGS;
      [[uuu]]iii) Benzethonium chloride, Propylene Glycol, vitamine E TPGS;
      [[vvv]]jjj) Benzethonium chloride, vitamine E TPGS;
      [[xxx]]kkk) Cremophor EL, Polysorbate 80;
      [[yyy]]III) Cremophor EL, Deoxycholate, Poloxamer 237;
      [[zzz]]mmm) Cremophor EL, Deoxycholate, vitamine E TPGS;
      [[aaaa]]nnn) Cremophor EL, Poloxamer 407;
      [[bbbb]]000) Deoxycholate, Poloxamer 237;
      [[cccc]]ppp) Deoxycholate, Poloxamer 237, Poloxamer 338;
      [[dddd]]qqq) Deoxycholate, Poloxamer 237, Poloxamer 407;
      [[eeee]]rrr) Deoxycholate, Poloxamer 237, Polysorbate 80;
      [[ffff]]sss) Deoxycholate, Poloxamer 237, vitamine E TPGS;
```

Amendment Dated March 2, 2007

```
[[gggg]]ttt) Deoxycholate, Poloxamer 407;
[[hhhh]]uuu) Deoxycholate, Poloxamer 407, Polysorbate 80;
[[iiii]]vvv) Deoxycholate, Polysorbate 80, vitamine E TPGS;
[[jjjj]]www) Deoxycholate, vitamine E TPGS;
[[kkkk]]xxx) PEG 400, Poloxamer 237;
[[IIII]]yyy) PEG 400, Poloxamer 237, Poloxamer 338;
[[mmmm]]zzz) PEG 400, Poloxamer 237, Poloxamer 407;
[[nnnn]]aaaa) PEG 400, Poloxamer 407;
[[rrrr]]bbbb) Poloxamer 237, Poloxamer 338;
[[ssss]]cccc) Poloxamer 237, Poloxamer 407;
[[uuuu]]dddd) Poloxamer 338, Poloxamer 407;
[[xxxx]]eeee) Poloxamer 237, Poloxamer 338;
[[yyyy]]ffff) Poloxamer 237, Poloxamer 407;
[[zzzz]]qqqq) Poloxamer 237, Polyoxyethylene 40 Stearate;
[[aaaaa]]hhhh) Poloxamer 237, Polysorbate 80;
[[bbbbb]]iiii) Poloxamer 237, Propylene Glycol;
[[ccccc]]iiii) Poloxamer 237, vitamine E TPGS;
[[ddddd]]kkkk) Poloxamer 237, Saccharin sodium;
[[fffff]]IIII) Poloxamer 237, Poloxamer 338;
[[ggggg]]mmmm) Poloxamer 237, Poloxamer 338, Poloxamer 407;
[[hhhhh]]nnnn) Poloxamer 237, Poloxamer 338, vitamine E TPGS;
[[iiiii]]oooo) Poloxamer 237, Poloxamer 407;
[[jjjjj]]pppp) Poloxamer 237, Poloxamer 407, Polyoxyethylene 40 Stearate;
[[kkkkk]]qqqq) Poloxamer 237, Poloxamer 407, Polysorbate 80;
[[IIII]]rrrr) Poloxamer 237, Poloxamer 407, Propylene Glycol;
[[mmmmm]]ssss) Poloxamer 237, Poloxamer 407, Saccharin sodium;
[[nnnnn]]tttt) Poloxamer 237, Poloxamer 407;
[[ooooo]]uuuu) Poloxamer 237, Polyoxyethylene 40 Stearate, Polysorbate 80;
[[ppppp]]vvvv) Poloxamer 237, Polyoxyethylene 40 Stearate, vitamine E TPGS;
[[qqqqq]]wwww) Poloxamer 237, Polysorbate 80;
[[sssss]]xxxx) Poloxamer 338, Poloxamer 407;
[[ttttt]]vyvy) Poloxamer 338, Poloxamer 407;
[[uuuuu]]zzzz) Poloxamer 338, Poloxamer 407, Polyoxyethylene 40 Stearate;
```

Appln. No.: 10/629,308

Amendment Dated March 2, 2007

```
[[vvvvv]]aaaaa) Poloxamer 338, Poloxamer 407, Polysorbate 80;
      [[wwwww]]bbbbb) Poloxamer 338, Poloxamer 407, Propylene Glycol;
      [[xxxxx]]cccc) Poloxamer 338, Poloxamer 407, vitamine E TPGS;
      [[yyyyy]]ddddd) Poloxamer 338, Poloxamer 407, Saccharin sodium;
      [[aaaaaa]]eeeee) Poloxamer 338, Polyoxyethylene 40 Stearate, Polysorbate 80;
      [[bbbbbb]]fffff) Poloxamer 338, Polyoxyethylene 40 Stearate, vitamine E TPGS;
      [[dddddd]]gqqqq) Poloxamer 407, Polyoxyethylene 40 Stearate;
      [[eeeeee]]hhhhh) Poloxamer 407, Polysorbate 80;
      [[ffffff]]iiiii) Poloxamer 407, Propylene Glycol;
      [[gggggg]]jijii) Poloxamer 407, vitamine E TPGS;
      [[hhhhhh]]kkkkk) Poloxamer 407, Saccharin sodium;
      [[kkkkkk]][IIII]) Poloxamer 407, Polyoxyethylene 40 Stearate, Polysorbate 80;
      [[mmmmmm]]mmmmm) Polyoxyethylene 40 Stearate, Polysorbate 80;
      [[nnnnnn]]nnnnn) Polysorbate 80, vitamine E TPGS;
      [[pppppp]]ooooo) Polysorbate 80, Propylene Glycol 12;
      [[qqqqq]]ppppp) Polysorbate 80, Propylene Glycol;
      [[yyyyyy]]qqqqq) Poloxamer 237, Poloxmer 407;
      [[aaaaaaa]]rrrrr) Sodium deoxcholate, polyoxyethylene 20 sorbitan monooleate,
D-alpha-tocopheryl polyethylene glycol 100 succinate;
      [[bbbbbbb]]ssss) Poloxamer 237, PEG-40 stearate, polyoxyethylene 20 sorbitan
monooleate;
      [[ccccccc]]ttttt) PEG-400, PEG-40 stearate, polyoxyethylene 20 sorbitan
monooleate;
      [[ddddddd]]uuuuu) Poloxamer 237, PEG-400;
      [[eeeeeee]]vvvvv) Sodium deoxcholate, D-alpha-tocopheryl polyethylene glycol
100 succinate;
      [[fffffff]]wwwww) polyoxyethylene 20 sorbitan monooleate, propylene glycol,
PEG-400, citric acid;
      PEG 400 propylene glycol; and
      [[iiiiii]]xxxxx) PEG 400, propylene glycol, Tween.
      4.
             (Previously Presented) The composition of Claim 1, wherein:
      a) said propofol is present in a concentration of about 0.5 to 10% (w/v);
```

Appln. No.: 10/629,308

Amendment Dated March 2, 2007

- b) said propofol is present in a concentration of about 0.5 to 5% (w/v);
- c) said propofol is present in a concentration of about 1 to 3% (w/v); or
- d) said propofol is present in a concentration of about 1% (w/v).
- 5. (Currently Amended) The composition of Claim $\frac{12}{2}$, wherein:
- a) said excipients are present in a concentration of about 0.1 to 25% (w/v);
- b) said excipients are present in a concentration of about 0.5 to 10% (w/v); or
- c) said excipients are present in a concentration of about 1 to 5% (W/V).
- 6. (Currently Amended) The composition of Claim $\frac{12}{2}$, wherein:
- a) said composition comprises poloxamer 188, polyethylene glycol 400, and propylene glycol:
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
 - b) said composition comprises poloxamer 188 and polyethylene gycol 400:
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- c) said composition comprises poloxamer 188 (8% w/v), polyethylene glycol 400 (4% w/v), and propylene glycol (1% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- d) said composition comprises poloxamer 188 (8% w/v), polyethylene glycol 400 (3% w/v), and propylene glycol (1% w/v):

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

(i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;

- e) said composition comprises poloxamer 188 (8% w/v), polyethylene glycol 400 (2% w/v), and propylene glycol (1% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- f) said composition comprises poloxamer 188 (8% w/v) and polyethylene glycol 400 (3% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- g) said composition comprises poloxamer 188 (8% w/v) and polyethylene glycol 400 (2% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- h) said composition comprises poloxamer 188 (8% w/v) and polyethylene glycol 400 (4% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- i) said composition comprises poloxamer 188 (7% w/v), polyethylene glycol 400 (3% w/v), and propylene glycol (1% w/v):

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

(i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;

- j) said composition comprises poloxamer 188 (7% w/v) and polyethylene glycol 400 (3% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- i) said composition comprises poloxamer 188 (7% w/v), polyethylene glycol 400 (2% w/v), and propylene glycol (1% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- j) said composition comprises poloxamer 188 (7% w/v) and polyethylene glycol 400 (2% w/v)
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- k) said composition comprises poloxamer 188 (6% w/v), polyethylene glycol 400 (4% w/v), and propylene glycol (1% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal;
- l) said composition comprises poloxamer 188 (6% w/v), polyethylene glycol 400 (4% w/v), and propylene glycol (2% w/v):

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

(i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal; or

- m) said composition comprises poloxamer 188 (9% w/v) and polyethylene glycol 400 (2% w/v):
 - (i) wherein said composition further comprises one or more compound selected from citric acid, disodium edetate, metabisulfate, benzyl alcohol, an antioxidant, a preservative, an antimicrobial agent, or a microbicidal.
 - 7. (Canceled)
 - 8. (Previously Presented) The composition of Claim 1, wherein:
 - a) said composition has a particle size diameter of between 25 and 200 nm;
 - b) said composition has a particle size diameter of between 50 and 100 nm; or
 - c) said composition forms particles of similar particle size.
 - 9. (Previously Presented) The composition of Claim 1, wherein:
 - a) said composition does not support microbial growth;
 - b) said composition is microbicidal; or
- c) said composition is sufficient for no more than a 10-fold increase in growth, of Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027 or Candida albicans ATCC 10231 for at least 24 hours.
 - 10. (Previously Presented) The composition of Claim 1, wherein:
- a) said composition is functionally bioequilavent to commercial lipid based anesthetic products:
 - (i) wherein said bioequilavence is demonstrated in dogs;
 - (ii) wherein said bioequilavence is demonstrated in humans; or
- b) said composition has a red blood cell blood plasma partition coefficient greater than that of commercial lipid based anesthetic products:

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

(i) wherein said partition coefficient for said composition is between about 2 and 4.

11. (Previously Presented) The composition of Claim 1, further comprising:

- a) an acid;
- b) a base;
- c) a local anesthetic;
- d) a second general anesthetic;
- e) an antimicrobial agent;
- f) a surfactant;
- g) a tonicity modifier;
- (i) wherein said tonicity modifier is glycerol;
- h) a pH modifier; or
- j) a second, third, fourth, fifth, or sixth excipient.
- 12. (Previously Presented) The composition of Claim 1, wherein said composition is substantially free of:
 - a. a lipid, a long chain fatty acid, triacylglycerol, or glycerol ester;
 - b. an antimicrobial agent; or
 - c. a preservative.
- 13. (Currently Amended) The composition of Claim ± 2 , wherein said one or more additional excipients comprise a purified poloxamer:
- a) wherein said purified poloxamer has a polydispersirty value of between about 5 and 1, about 4 and 1, about 3 and 1, about 2 and 1, or about 1.1 and 1.
 - 14. (Currently Amended) The composition of Claim $\frac{12}{2}$, wherein:
- a) said propofol is present in a concentration of about 0.5 to about 1.5 percent (w/v);

J&J-100US

Appln. No.: 10/629,308 Amendment Dated March 2, 2007

- b) said propofol is present in a concentration of about 0.9 to about 1.1 percent (w/v);
- c) said composition comprises D-alpha-tocopheryl polyethylene glycol 1000 succinate and in a concentration of about 1 to about 5 percent (w/v);
- d) said composition comprises sodium deoxycholate in a concentration of about 1.5 to about 6 percent (w/v);
- e) said composition comprises polyoxyethylene 20 sorbitan monooleate, D-alphatocopheryl polyethylene glycol 1000 succinate, and sodium deoxycholate in a total concentration of about 15 percent or less (w/v);
- f) said composition comprises citric acid or a salt thereof in a concentration of at least about 0.1 percent (w/v);
- g) said composition comprises water, 2,6-diisopropylphenol, polyoxyethylene 20 sorbitan monooleate, D-alpha-tocopheryl polyethylene glycol 1000 succinate, sodium deoxycholate, optionally, a tonicity modifier, and optionally, a pH modifier;
- h) said composition comprises water, 2,6-diisopropylphenol, polyoxyethylene 20 sorbitan monooleate, D-alpha-tocopheryl polyethylene glycol 1000 succinate, sodium deoxycholate, and optionally, citric acid or a salt thereof;
- i) said composition comprises about 0.5 to about 2.4 percent (w/v) of 2,6-diisopropylphenol; about 1 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 0.5 to about 15 percent (w/v) of D-alpha-tocopheryl polyethylene glycol 1000 succinate; and about 1 to about 15 percent (w/v) of sodium deoxycholate;
- j) said composition comprises about 0.5 to about 2.4 percent (w/v) of 2,6-disopropylphenol; about 2 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 0.5 to about 15 percent (w/v) of Poloxamer 237; and about 1 to about 15 percent (w/v) of polyethylene glycol 40 stearate;
- k) said <u>additional</u> excipient is polyoxyethylene 20 sorbitan monooleate in a concentration of about 3 to about 7 percent (w/v);

J&J-100US

Appln. No.: 10/629,308

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

I) said <u>additional</u> excipient is Poloxamer 237 in a concentration of about 1 to about 5 percent (w/v);

- m) said <u>additional</u> excipient is polyethylene glycol 40 stearate in a concentration of about 1.5 to about 6 percent (w/v);
- n) said composition comprises polyoxyethylene 20 sorbitan monooleate, Poloxamer 237, and polyethylene glycol 40 stearate in a total concentration of about 15 percent or less (w/v);
- o) said composition comprises water, propofol, polyoxyethylene 20 sorbitan monooleate, Poloxamer 237, polyethylene glycol 40 stearate, optionally, a tonicity modifier, and optionally, a pH modifier;
- p) said composition comprises propofol, polyoxyethylene 20 sorbitan monooleate, Poloxamer 237, polyethylene glycol 40 stearate, and, optionally, citric acid or a salt thereof;
- q) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 2 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 0.5 to about 15 percent (w/v) of Poloxamer 237; and about 1 to about 15 percent (w/v) of polyethylene glycol 40;
- r) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 2 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 2 to about 20 percent (w/v) of polyethylene glycol 400; and about 0.1 to about 15 percent (w/v) of polyethylene glycol 40 stearate;
- s) said composition comprises water, propofol, polyoxyethylene 20 sorbitan monooleate, polyethylene glycol 400, polyethylene glycol 40 stearate, optionally, a tonicity modifier, and optionally, a pH modifier;
- t) said composition comprises water, propofol, polyoxyethylene 20 sorbitan monooleate, polyethylene glycol 400, polyethylene glycol 40 stearate, and, optionally, citric acid or a salt thereof;

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

u) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 2 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 2 to about 20 percent (w/v) of polyethylene glycol 400; and about 0.1 to about 15 percent (w/v) of polyethylene glycol 40 stearate;

- v) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 3 to about 20 percent (w/v) of polyethylene glycol 400; and about 1 to about 15 percent (w/v) of Poloxamer 237;
- x) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 1 to about 15 percent (w/v) of sodium deoxycholate; and about 2 to about 15 percent (w/v) of D-alpha-tocopheryl polyethylene glycol 1000 succinate; or
- y) said composition comprises about 0.5 to about 2.4 percent (w/v) of propofol; about 0.5 to about 15 percent (w/v) of polyoxyethylene 20 sorbitan monooleate; about 0.5 to about 15 percent (w/v) of propylene glycol; about 1 to about 20 percent (w/v) of polyethylene glycol 400; and about 2 to about 15 percent (w/v) of Poloxamer 188.

15.-16. (Canceled)

- 17. (Withdrawn) A sterile, aqueous pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol and one or more excipients, wherein said one or more excipients comprise a solvent for propofol that is present in an amount of less than about 10 % (w/v), wherein said composition is stored in a container having a means for dispensing the composition, and wherein said composition does not exhibit substantial propofol degradation.
- 18. (Withdrawn) The sterile pharmaceutical composition of claim 17, wherein said composition further comprises a solvent for propofol.
- 19. (Withdrawn) The sterile pharmaceutical composition of claim 18, wherein the solvent is a water-immiscible solvent.
- 20. (Withdrawn) The sterile pharmaceutical composition of claim 19, wherein the water-immiscible solvent is selected from the group consisting of soybean oil,

J&J-100US

Appln. No.: 10/629,308

Amendment Dated March 2, 2007

Reply to Office Action of December 22, 2006

sunflower oil, arachis oil, castor oil, an ester of medium or long-chain fatty acid, hydrogenated castor oil, and mixtures thereof.

- 21. (Withdrawn) The sterile pharmaceutical composition of claim 20, wherein the water-immiscible solvent is soybean oil.
- 22. (Withdrawn) The sterile pharmaceutical composition of claim 18, wherein the solvent is selected from the group consisting of ethanol, polyethylene glycols, and mixtures thereof.
- 23. (Withdrawn) The sterile pharmaceutical composition of claim 18, wherein the means for dispensing the composition does not cause substantial propofol degradation.
- 24. (Withdrawn) A sterile pharmaceutical composition for parenteral administration of propofol, said composition comprising propofol and less than about 10 % by weight solvent for propofol, wherein said composition is stored in a container having a closure, wherein said closure is inert to propofol.